Gainers:

Abivax (+11%): After plunging nearly 40% at the start of the week, the French biotech is seeing a rebalancing. The move is accompanied by several analyst adjustments: Portzamparc remains at 'hold' and raises its price target from 63 to 70 EUR, while Stifel maintains its 'buy' rating despite lowering its target from 142 to 115 EUR.

Remy Cointreau (+9%): The spirits group announced a return to sustainable organic revenue growth, with a gradual improvement in momentum for the 2026-2027 fiscal year. The group is also targeting a slight organic improvement in current operating margin. Results for the fiscal year ended March were in line with its expectations and slightly ahead of analyst consensus.

Puma (+4%): The sportswear company is benefiting from a positive recommendation from Citi. The bank upgraded the stock from 'neutral' to 'buy' with a price target raised to 35 EUR, up from 27.50 EUR previously.

Capgemini (+3%): The consulting and IT services group is supported by BofA, which reiterated its 'buy' rating with a price target of 139 EUR. The bank highlighted growth opportunities related to agentic AI, a theme presented as a multi-year driver to support corporate transformation.

Maire (+2%): The Italian company announced that its subsidiary Tecnimont has been awarded additional work worth approximately 900 MUSD as part of a major onshore project. This additional scope aims to support the optimization of existing oil and gas facilities.

Decliners:

Sivers Semiconductors (-15%): After soaring more than 2000% this year, the Swedish group saw its division director sell his entire stake for 100 MSEK. The market views this as a sign of divestment, which is intensifying profit-taking.

Universal Music (-6%): Billionaire Bill Ackman, through his hedge fund Pershing Square, plans to divest his stake in Universal Music. Bank of America will orchestrate the sale of 80.6 million shares within a price range of 17.66 EUR to 18.62 EUR per share.

Roche Holding (-5%): The Swiss healthcare group failed to sway Jefferies' opinion. Analyst Michael Leuchten maintains his 'sell' rating with a price target of 230 CHF, nearly 25% below the current share price.

Pirelli (-5%): American short-seller Grizzly Research has taken a short position on the tire manufacturer. The firm is notably known for its report on Temu regarding spyware, which served as the basis for several lawsuits.